Indication
Estrogen receptor (ER)-positive, HER2-negative postmenopausal advanced breast cancer
Estrogen receptor (ER)-positive, HER2-negative postmenopausal advanced breast cancer refers to a locally advanced or metastatic malignancy of the mammary epithelium occurring in individuals who have experienced the permanent cessation of ovarian function. Read more about Estrogen receptor (ER)-positive, HER2-negative postmenopausal advanced breast cancer
7 drugs 7 manufacturers
Drugs that treat it
Common Estrogen receptor (ER)-positive, HER2-negative postmenopausal advanced breast cancer therapies.
TORPENZ (everolimus)
EVEROLIMUS
EVEROLIMUS
AFINITOR (everolimus)
EVEROLIMUS
YULITHIRA (everolimus)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonEstrogen receptor (ER)-positive, HER2-negative postmenopausal advanced breast cancer refers to a locally advanced or metastatic malignancy of the mammary epithelium occurring in individuals who have experienced the permanent cessation of ovarian function.
Pathophysiologically, the tumor cells express estrogen receptors that promote hormone-driven cellular proliferation, while lacking overexpression of human epidermal growth factor receptor 2 protein or *ERBB2* gene amplification.
The advanced stage denotes disease that has spread extensively within local tissues, regional lymphatics, or distant organs, rendering it generally incurable with curative-intent surgery.
This biological subtype represents the most common form of advanced breast cancer and is primarily managed with systemic endocrine-based regimens.
- cancernetwork.com
Estrogen receptor (ER)-positive, HER2-negative postmenopausal advanced breast cancer refers to a locally advanced or metastatic malignancy of the mammary epithelium occurring in individuals who have experienced the permanent cessation of ovarian function Pathophysiologically, the tumor cells express estrogen receptors that promote hormone-driven cellular proliferation, while lacking overexpression of human epidermal growth factor receptor 2 protein or *ERBB2* gene amplification The advanced stag...
- webmd.com
Estrogen receptor (ER)-positive, HER2-negative postmenopausal advanced breast cancer refers to a locally advanced or metastatic malignancy of the mammary epithelium occurring in individuals who have experienced the permanent cessation of ovarian function The advanced stage denotes disease that has spread extensively within local tissues, regional lymphatics, or distant organs, rendering it generally incurable with curative-intent surgery
- clevelandclinic.org
Pathophysiologically, the tumor cells express estrogen receptors that promote hormone-driven cellular proliferation, while lacking overexpression of human epidermal growth factor receptor 2 protein or *ERBB2* gene amplification This biological subtype represents the most common form of advanced breast cancer and is primarily managed with systemic endocrine-based regimens
Personalize your experience
Follow Estrogen receptor (ER)-positive, HER2-negative postmenopausal advanced breast cancer and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.